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Abstract
Background: Neurotensin (NT) is known to act on dopamine (DA) neurons at the
somatodendritic level to regulate cell firing and secondarily enhance DA release. In addition,
anatomical and indirect physiological data suggest the presence of NT receptors at the terminal
level. However, a clear demonstration of the mechanism of action of NT on dopaminergic axon
terminals is lacking. We hypothesize that NT acts to increase DA release by inhibiting the function
of terminal D2 autoreceptors. To test this hypothesis, we used fast-scan cyclic voltammetry (FCV)
to monitor in real time the axonal release of DA in the nucleus accumbens (NAcc).
Results: DA release was evoked by single electrical pulses and pulse trains (10 Hz, 30 pulses).
Under these two stimulation conditions, we evaluated the characteristics of DA D2 autoreceptors
and the presynaptic action of NT in the NAcc shell and shell/core border region. The selective
agonist of D2 autoreceptors, quinpirole (1 μM), inhibited DA overflow evoked by both single and
train pulses. In sharp contrast, the selective D2 receptor antagonist, sulpiride (5 μM), strongly
enhanced DA release triggered by pulse trains, without any effect on DA release elicited by single
pulses, thus confirming previous observations. We then determined the effect of NT (8–13) (100
nM) and found that although it failed to increase DA release evoked by single pulses, it strongly
enhanced DA release evoked by pulse trains that lead to prolonged DA release and engage D2
autoreceptors. In addition, initial blockade of D2 autoreceptors by sulpiride considerably inhibited
further facilitation of DA release generated by NT (8–13).
Conclusion: Taken together, these data suggest that NT enhances DA release principally by
inhibiting the function of terminal D2 autoreceptors and not by more direct mechanisms such as
facilitation of terminal calcium influx.
Background
Neurotensin (NT) is a peptide originally isolated from
bovine hypothalamus [1]. It is found in the CNS and gas-
trointestinal tract. In the CNS, NT acts as a neurotransmit-
ter or neuromodulator and one of its better known actions
is to modulate dopaminergic transmission within the
mesolimbic and nigrostriatal pathways [2]. In addition, a
number of studies suggest that NT may be implicated in
the pathophysiology of CNS disorders including schizo-
phrenia, Parkinson's disease and drug abuse [2-5].
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NT acts to enhance dopamine (DA) release. When applied
to the ventral tegmental area (VTA), NT increases the fir-
ing rate of DA neurons and DA release in terminal fields
of the nucleus accumbens (NAcc) and the prefrontal cor-
tex[6-8]. Moreover, acute microinjection of NT into the
VTA enhances motor activity and facilitates DA-depend-
ent behaviors[5,6,8]. At a mechanistic level, recent work
has established that somatodendritic NT receptors
enhance the firing rate of DA neurons through a Ca2+-
dependent mechanism [9].
At the terminal level, NT also acts to enhance DA release.
First, anatomical evidence for a presynaptic localization of
NT receptors has been provided [10-12]. Second, NT facil-
itates K+-evoked and electrically-evoked DA release in dor-
sal striatal slice preparations [13,14] as well as in dorsal
striatum in vivo [15]. These results support a presynaptic
effect of NT on DA neuron axon terminals, but previous
studies have not identified the mechanism involved or
excluded an indirect mechanism of action. Recent work
studying glutamate cotransmission in cultured DA neu-
rons failed to provide support for a direct excitatory effect
of NT on axon terminals [16]. In addition, a previous pre-
liminary report failed to detect an enhancement of DA
release evoked by single electrical pulses in NAcc slices
[17]. Thus, the mechanism of action of NT on dopamin-
ergic axon terminals remains unclear.
In the present study, we used fast-scan cyclic voltammetry
(FCV) to better characterize the presynaptic action of NT
in the NAcc. We find that although NT fails to increase DA
release evoked by single pulses, it strongly enhances DA
release evoked by pulse trains that lead to prolonged DA
release and engage D2 autoreceptors. Our results suggest
that NT acts to enhance DA release by inhibiting the func-
tion of terminal D2 autoreceptors.
Results
Time course of DA overflow evoked by single-pulses and 
train-pulses in the nucleus accumbens
Fast-scan cyclic voltammetry was used to monitor DA
release at high time resolution in the shell and core/shell
border region of Sprague-Dawley rat NAcc slices. We
recorded DA overflow following single-pulse (400 μA, 1
ms) and in response to train-pulse stimulations (30 pulses
delivered at 10 Hz), a frequency that can occur during
bursting in vivo (Fig. 1A). The released substance was iden-
tified as DA since the oxidation currents recorded corre-
sponded to the peak oxidation potential for DA (~+600
mV) (Fig. 1B). With train stimulation, DA concentrations
peaked at 1.13 ± 0.18 μM (n = 5). DA concentrations rose
to a maximum within ~400 ms (n = 5). The return to base-
line was reached approximately 6 seconds after the peak
signal and the signal width at half-height was ~2.2 s (n =
5). With single-pulse stimulation, DA levels reached a
peak at 0.48 ± 0.09 μM (n = 5). DA concentrations rose to
their maximum within ~200 ms (n = 5). The return to
baseline was observed approximately one second after the
peak and the signal width at half-height was ~0.4 s (n = 5).
A significant difference was detected between the two
stimulation conditions for the peak DA levels reached
(Student's t-test, t = 5.07, p < 0.001). As expected, the
release of DA evoked by electrical stimulation of the NAcc
was blocked by TTX (1 μM) (15.3 ± 8.2% of control, n =
3) and was thus action potential-dependent, as well as by
the removal of extracellular calcium (17.2 ± 11.0% of con-
trol, n = 6, with 0.5 mM Ca2+; and 10.5 ± 6.4% of control
values, n = 2, with 0 mM Ca2+) (Fig. 2).
NT facilitates DA overflow evoked by train-pulses but not 
by single-pulses
We next evaluated the effect of NT on electrically-evoked
DA overflow in the NAcc. Using single electrical pulses, we
found that at a saturating concentration [9], NT (8–13)
(100 nM) failed to alter DA overflow (94.4 ± 5.5% of con-
trol; Student's t-test, t = 0.23, p > 0.05, n = 5), suggesting
that DA release is not directly facilitated by NT (Fig. 3A,
B). In sharp contrast, using train-pulse stimulation, NT
significantly enhanced peak DA overflow to 143.1 ± 6.8%
of control (Student's t-test, t = 3.98, p = 0.001, n = 13)
(Fig. 3A, C). The facilitatory effect started to decline before
the end of the period of agonist application: DA concen-
trations recorded after 8 min of NT application were lower
than after 6 min (one-way ANOVA performed on time, T
= 0 to T = 36, followed by post hoc Tukey tests, F = 13.81,
p < 0.001). This observation is compatible with the
Time course of evoked DA overflow in the nucleus accumbensF g re 1
Time course of evoked DA overflow in the nucleus 
accumbens. A) Average evoked DA overflow following sin-
gle-pulse (400 μA, 1 ms/pulse, n = 5) and train-pulse (400 μA, 
0.1 ms/pulse, 30 pulses at 10 Hz, n = 5) stimulations. B) Sam-
ple cyclic voltammogram. The voltammogram was obtained 
at the peak of evoked DA overflow under control condi-
tions. The positions of the oxidation and reduction peaks are 
compatible with the fact that the species detected was DA. Page 2 of 8
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tize in response to sustained stimulation [18]. In accord-
ance with this, the preferential NTR1 antagonist SR42948
(1 μM) completely prevented the facilitatory effect of NT
(peak overflow 100.8 ± 5.7% of control; t = 0.376 p >
0.05, n = 5) (results not shown).
NT enhances DA release through inhibition of D2 
autoreceptor function
Previous work has suggested that NT may decrease termi-
nal D2 receptor function [16,19-21]. One interpretation of
the ability of NT to facilitate train-evoked but not single
pulse-evoked DA overflow is therefore that NT acts princi-
pally by inhibiting the function of terminal D2 autorecep-
tors. This would imply that contrarily to train stimulation,
D2 autoreceptors are usually not activated in response to
single pulse stimulation, as was previously demonstrated
[22-25]. To evaluate this hypothesis under our conditions,
we next quantified evoked DA overflow using selective
agonists and antagonists of the D2 autoreceptor. The D2
receptor agonist quinpirole (1 μM) decreased pulse train-
evoked DA overflow to 27.9 ± 2.5% of control (Student's
t-test, t = 12.33, p < 0.001, n = 3) (Fig. 4A, B) and single
pulse-evoked DA overflow to 19.8 ± 8.7% of control (Stu-
dent's t-test, t = 10.24, p < 0.001, n = 4) (Fig. 4C). In con-
trast, the D2 receptor antagonist sulpiride (5 μM)
enhanced DA release triggered by pulse trains (175.3 ±
4.1% of control; Student's t-test, t = 14.4, p < 0.001, n = 8)
(Fig. 4A, B), but had no effect on DA overflow evoked in
response to single pulses (87.3 ± 1.7% of control values,
Student's t-test, t = 1.40, p > 0.05, n = 4) (Fig. 4C).
We next tested whether NT still increased DA overflow fol-
lowing D2 receptor blockade. We first applied sulpiride (5μM) alone and found that it increased DA levels to 181.5
± 3.1% of control values (n = 10) (Fig. 5A). With sulpiride
Dependence of DA overflow on cell firing and extracellular calcium concentrationsFigure 2
Dependence of DA overflow on cell firing and extra-
cellular calcium concentrations. Graph comparing the 
time course of DA overflow following train-pulse stimula-
tions under control conditions (2.4 mM calcium) (n = 5) or in 
the presence of 1 μM TTX (n = 3), 0.5 mM calcium (n = 6) or 
0 mM calcium (n = 2).
Neurotensin facilitates train pulse- but not single pulse-evoked DA overflow in the NAccFig re 3
Neurotensin facilitates train pulse- but not single 
pulse-evoked DA overflow in the NAcc. A) Graphs rep-
resenting the average amplitude and kinetics of single-pulse 
(lower traces) and train-pulse (upper traces) evoked DA 
overflow in the presence of NT (8–13) (100 nM) compared 
to control. B) Time course of peak DA overflow evoked by 
single electrical pulses. NT (8–13) (100 nM) was applied for a 
total of 8 min. It exerted no effect on single pulse-evoked DA 
overflow (n = 5). C) Time course of peak DA overflow 
evoked by train pulses. NT (8–13) strongly enhanced train-
evoked DA overflow (n = 13). Data are expressed as a per-
centage of the DA levels recorded during the control period 
before NT.Page 3 of 8
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minor additional increase in DA levels (to 194.1 ± 4.6%
of the control level, n = 10), thus reflecting an almost
complete block of the facilitating effect of NT (Fig. 5A, B).
A one-way ANOVA with post hoc Tukey tests revealed a sig-
nificant difference between control and these two condi-
tions (sulpiride and sulpiride + NT) (F = 3.57, p < 0.05).
A specific comparison of the enhancement of DA overflow
by NT in the presence of sulpiride (12.7 ± 4.3% above
sulpiride alone) or in its absence (43.1 ± 6.8% above con-
trol) shows that the effect of NT was strongly decreased
under autoreceptor blockade (Student's t-test, t = 3.51, p =
0.002). These results suggest that the majority of the facil-
itatory effect of NT on DA release is mediated through
inhibition of D2 autoreceptor function.
Activation of D2 autoreceptors during train pulse- but not single pulse-evoked DA overflowFigure 4
Activation of D2 autoreceptors during train pulse- 
but not single pulse-evoked DA overflow. A) The 
graphs represent the average amplitude and kinetics of train-
evoked DA overflow in the presence of 5 μM sulpiride (left) 
or 1 μM quinpirole (right). B) Graph showing the effect of 
the D2 receptor agonist quinpirole (1 μM; n = 3), and the D2 
receptor antagonist sulpiride (5 μM; n = 8) on DA overflow 
following pulse-train stimulation. Activation of D2 receptors 
by quinpirole inhibits peak DA overflow, whereas the block-
ade of these receptors by sulpiride considerably enhances it. 
C) Graph comparing the effect of quinpirole (1 μM; n = 5), 
and sulpiride (5 μM; n = 4) on DA overflow evoked by single-
pulse stimulation. Under these conditions, D2 receptor acti-
vation also inhibits DA overflow, but D2 receptor blockade 
has no effect.
NT enhances train-pulse evoked DA overflow through inhi-bition of D2 autoreceptor functionFigure 5
NT enhances train-pulse evoked DA overflow 
through inhibition of D2 autoreceptor function. A) 
Sulpiride (5 μM) alone was first pre-applied. With sulpiride 
present in the bath, NT (8–13) (100 nM) was introduced for 
a total of 8 min. The graphs represent the average amplitude 
and kinetics of train pulse-evoked DA overflow recorded 
during the control period (left), in the presence of sulpiride 
alone (middle) and in the presence of both NT (8–13) + 
sulpiride (right) (n = 10). Sulpiride alone enhanced peak DA 
overflow by 81% compared to control. In the presence of 
sulpiride, NT (8–13) only caused a small additional increase 
in DA levels (by 13% compared to the sulpiride alone condi-
tion) (n = 10). B) Summary graph showing the time course of 
the effect of NT (8–13) on peak DA overflow evoked by 
train-pulse stimulation following D2 receptor blockade by 
sulpiride (n = 10).Page 4 of 8
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sulpiride
Pulse trains generate considerable DA release in the NAcc
brain slice in the presence of sulpiride (maximal increase
of 2.2 μM in the presence of both sulpiride and NT). The
blockade by sulpiride of the ability of NT to facilitate DA
release could thus in principle be an artefact resulting
from a ceiling effect due to depletion of the releasable
pools of DA or to the inability to further increase release
probability. To test this possibility, we pre-applied sulpir-
ide (5 μM) and then introduced a modified aCSF contain-
ing an elevated concentration of calcium (3.4 mM Ca2+).
Sulpiride first increased DA overflow to 173.6 ± 6.9% of
control levels (n = 7) (Fig. 6A). Elevation of extracellular
Ca2+ to 3.4 mM in the presence of sulpiride produced an
additional increased to 258.1 ± 15.1% of control (n = 7)
(Fig. 6A, B). A one-way ANOVA followed by a post hoc
Tukey test confirmed significant differences between the
control, sulpiride and 3.4 mM Ca2+ conditions (F = 5.57,
p < 0.001). The maximal DA release detected with sulpir-
ide and elevated Ca2+ exceeded 3.0 μM. Thus, the block-
ade by sulpiride of the ability of NT to facilitate DA release
is not likely to simply result from a depletion of releasable
pools of DA or to an inability to further increase release
probability.
Discussion
Although multiple aspects of the action of NT at the cell
body level in the VTA have been investigated [26-28], the
mechanism of action of NT on dopaminergic axon termi-
nals is still unclear. The present results provide new
insight into the mechanism mediating the facilitation of
DA release by NT at the level of axon terminals in the
NAcc. We show that this mechanism implicates a decrease
by NT of the effectiveness of terminal D2 autoreceptors
that normally inhibit DA release. We also demonstrate
that the effects of NT on DA release differ greatly depend-
ing on the electrical stimulation parameters used to elicit
this release. On the one hand, NT fails to alter DA over-
flow triggered by single pulses in the NAcc. On the other
hand, NT strongly enhances DA release evoked by pulse
trains that generate prolonged DA release and strongly
engage D2 autoreceptors.
An indirect mechanism can be discounted
NT is known to facilitate K+ and electrically-evoked DA
release in dorsal striatal slice preparations [13,14] as well
as in vivo [15]. Although these observations imply a pres-
ynaptic effect of NT on dopaminergic axon terminals, pre-
vious results have not excluded an indirect mechanism of
action. For example, NT could act through receptors
located in the striatum on other elements than dopamin-
ergic axon terminals. These receptors could for instance be
located on corticostriatal glutamatergic axon terminals. If
this were the case, NT could facilitate the spontaneous
release of glutamate, which would then enhance DA
release by depolarizing dopaminergic axon terminals.
Although we cannot formally exclude this possibility or
other possible indirect mechanisms, a major role for
glutamate in mediating the ability of NT to enhance train-
evoked DA overflow is not easily reconcilable with our
observation that this facilitatory effect of NT is blocked in
the presence of the D2 antagonist sulpiride. However, we
cannot exclude a possible partial implication of postsyn-
aptic D2 receptors located on NAcc medium spiny neu-
rons, through some retrograde signaling mechanism.
Action of NT on axon terminals
Previous experiments have explored the characteristics of
DA D2 autoreceptors under different stimulation condi-
tions varying the pulse/train duration or interpulse inter-
vals, but didn't directly address the issue of the control of
DA release by NT at the terminal level [22-25]. Nonethe-
Releasable pools of DA are not depleted in the presence of sulpirideFigure 6
Releasable pools of DA are not depleted in the pres-
ence of sulpiride. A) The graphs represent the average 
amplitude and kinetics of train pulse-evoked DA levels meas-
ured in the presence of sulpiride (5 μM) alone (+74% above 
control, n = 7) or sulpiride in the presence of an elevated 
concentration of extracellular Ca2+ (3.4 mM) (+ 84% above 
sulpiride alone, n = 7). B) Summary graph showing the time 
course of the effect of an elevation of extracellular Ca2+ to 
3.4 mM (for a total of 8 min) with pre-applied sulpiride (5 
μM) in the bath (n = 7).Page 5 of 8
(page number not for citation purposes)
BMC Neuroscience 2009, 10:96 http://www.biomedcentral.com/1471-2202/10/96less, a previous preliminary report showed that NT fails to
enhance DA release evoked by single electrical pulses in
NAcc slices [17], and suggested that DA release is not
directly facilitated by NT. This previous report is consist-
ent with our observation of an apparent lack of effect of
NT on DA overflow evoked by single pulses. Although this
finding could be taken as arguing against a role of termi-
nal NT receptors in regulating DA release, our findings
using train pulse-evoked release shed light on this para-
dox by showing that NT acts instead to enhance DA
release by inhibiting the function of terminal D2 autore-
ceptors. Our results support a recent report in which the
authors monitored glutamate co-release in cultured DA
neurons and found that NT does not directly increase
glutamate release, but rather attenuates the function of
presynaptic D2 receptors that otherwise inhibit glutamate
release [16].
Two of our present findings argue in favor of the hypoth-
esis that NT mainly acts to enhance DA release by inhibit-
ing the function of terminal D2 autoreceptors. First, we
show that only pulse train-evoked DA overflow is facili-
tated by NT. This observation is compatible with previous
reports showing that a minimum of 150–300 millisec-
onds is required for D2 autoreceptor activation to inhibit
DA release, conditions that are satisfied during train stim-
ulation, but are not optimal to inhibit release induced by
single short pulses [22-25]. In our experiments, the lack of
facilitation by sulpiride of single-pulse evoked DA over-
flow is in favor of this interpretation. Second, we demon-
strate that the facilitating effect of NT on pulse train-
evoked DA overflow is almost completely prevented by
pre-blockade of D2 receptors. An alternate interpretation
of this later finding is that in the presence of sulpiride, the
releasable pools of DA become depleted during stimulus
trains or the release probability cannot be further
increased, thus masking any subsequent facilitating effect
of NT. Considering our observation that elevating extra-
cellular Ca2+ strongly enhances DA overflow after pre-
application of sulpiride, this hypothesis of a ceiling effect
is unlikely. Nonetheless, we cannot completely exclude
that releasable pools of DA are modified in elevated extra-
cellular Ca2+. Alternate explanations of the ability of D2
receptor blockade to prevent the facilitating effect of NT
on DA release thus cannot completely be discounted.
Together, our results thus suggest that in the NAcc, NT acts
mainly by inhibiting the function of terminal D2 autore-
ceptors, leaving room for only a minor contribution of an
additional mechanism. Although this second mechanism
is presently unidentified, the capacity of NT receptors to
mobilize intracellular Ca2+ in DA neurons [9] leaves
opens the possible implication of a Ca2+-dependent prim-
ing of synaptic vesicles. Although we have not directly
examined the dorsal striatum in the present experiments,
our results are compatible with previous biochemical and
in vivo microdialysis work also suggesting that NT acts to
inhibit the function of terminal D2 autoreceptors in the
dorsal striatum [19-21,29].
In the present study, we found that the preferential NTR1
antagonist SR48692 prevented the facilitatory effect of NT
on train-evoked DA overflow. Although we cannot
exclude a partial contribution of the type 2 NT receptor
(NTR2), our finding is compatible with previous data
showing that DA neurons of the VTA and substantia nigra
express abundant levels of NTR1 [30,31], but only modest
amounts of NTR2 [32]. Second, the excitatory effects of
NT on DA neurons are maintained in NTR2 knockout
mice but strongly decreased in NTR1 knockout mice [33].
Compatible with this, SR48692 has been shown to block
the ability of NT to increase the firing rate of DA neurons
in culture [9]. Finally, SR48692 blocks the ability of NT to
reduce the effect of the D2 agonist pergolide on extracellu-
lar DA levels in the striatum in microdialysis experiments
[29].
Conclusion
In summary, our results provide a better understanding of
the mechanism of action of NT on dopaminergic axon ter-
minals. We suggest that NT through its type 1 receptor
enhances DA release mainly by inhibiting the function of
D2-type autoreceptors, thus disinhibiting DA release.
Future experiments should be oriented toward identifying
the specific mechanism involved, such as heterologous
desensitization of the D2 autoreceptor by NTR1 or direct
receptor-receptor interactions.
Methods
Animals and slice preparation
Experiments were performed in accordance with the Uni-
versité de Montréal animal ethics committee guidelines.
Sprague Dawley rats, aged 4 to 6 weeks, were lightly anaes-
thetized with halothane and decapitated. Their brains
were rapidly removed and transferred into ice-cold artifi-
cial cerebrospinal fluid (aCSF) containing: 125.2 mM
NaCl, 2.5 mM KCl, 26 mM NaHCO3, 0.3 mM anhydrous
KH2PO4, 2.4 mM anhydrous CaCl2, 1.3 mM anhydrous
MgSO4 and 10 mM D-glucose. NAcc brain slices were then
cut on a VT 1000s vibratome (Leica Microsystems, Nuss-
loch, Germany) at a thickness of 400 μm. The brain slices
were separated into right and left sections at the mid-sag-
ittal line after transfer to a holding chamber. Slices were
allowed to recover for 1 hour at room temperature in the
holding chamber in oxygenated (95% O2, 5% CO2) aCSF
and then transferred to a custom-built recording chamber
and perfused (1 ml/min) with aCSF at 35°C. For experi-
ments performed in the absence of extracellular calcium,
the composition of the zero calcium saline was NaCl 140
mM, KCl 5 mM, MgCl2 4 mM, EGTA 1 mM, Hepes 10 mM,
Sucrose 4 mM, Glucose 10 mM.Page 6 of 8
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Freshly-cut, disk carbon fibre electrodes of 5 μm diameter
were fabricated according to procedures described by
Kawagoe et al. [34] and by Kuhr and Wightman [35]. Elec-
trodes were backfilled with a 4.0 M potassium acetate
solution. The background current ranged from 50 to 180
nA. Fast-scan cyclic voltammetry was used to monitor DA
release [36]. A triangular voltage waveform (-400 to
+1000 mV at a rate of 300 V/s) was applied to the elec-
trode every 100 ms and was computer-controlled using
Clampex 9 software and a Digidata 1200B analog to dig-
ital converter (Axon Instruments, Union City, CA). This
voltage ramp was applied to the electrode via an Axopatch
200B amplifier (Axon Instruments, Union City, CA) in
voltage-clamp mode. The background-subtracted voltam-
mograms were used to identify the released substance.
Prior work has also established that the primary catecho-
lamine released in the rat NAcc slice is DA [37]. Calibra-
tion was performed in vitro for each working electrode
before and after the experiment in a 1 μM DA solution,
quantifying the peak of the oxidation current after adding
DA.
Electrical stimulation
Single-pulse or train-pulse electrical stimulations were
generated by an S-900 stimulator (Dagan, Minneapolis,
MN) and computer-triggered. Stimulations were applied
to the NAcc brain slice through a twisted bipolar tungsten
stimulation electrode (Plastics One, Roanoke, VA). The 2
stimulating electrode tips were separated by 100 to 150
μm and were gently placed on the surface of the NAcc
brain slice using a micromanipulator (Newport, Fountain
Valley, CA). Single-pulse (1 ms) and train-pulse (10 Hz,
30 pulses, 0.1 ms/pulse) stimuli were then generated to
evoke DA release. Pulse amplitude was 400 μA for both
single and train pulses.
Experimental design
The recording chamber was connected to a temperature-
controlled perfusion and aspiration system. The carbon
fibre electrode was then inserted ~75 μm into the slice by
a piezoelectric micromanipulator (Burleigh Instruments,
Victor, NY) and placed at approximately 100 μm in front
of the central position of the stimulating electrode tips.
After insertion of the carbon fibre electrode, the slice was
allowed to recuperate for at least 5 minutes before starting
recordings. Electrical stimulations were applied at inter-
vals of 2 minutes. The first 10 minutes served as a control
period. The peak of each response was measured and plot-
ted over time.
Drugs and chemicals
Chemicals were purchased from Sigma (St. Louis, MO)
except for tetrodotoxin (TTX) (Alomone laboratories,
Jerusalem, Israel). The 8–13 fragment of NT was used as a
NT receptor agonist. It was used at a concentration of 100
nM, shown to produce maximal effects in previous studies
[9]. The D2 receptor agonist quinpirole was used at a sat-
urating concentration of 1 μM, while the antagonist
sulpiride was used at a saturating dose of 5 μM, since
numerous previous physiological studies use these lig-
ands in the micromolar dose range [38-40]. Most drugs
were stored in aliquots at -20°C as stock solutions and
dissolved into aCSF immediately before use. Calcium,
magnesium and glucose were freshly added to the aCSF,
which was pre-oxygenated before use.
Statistical analysis
Data are provided as mean ± SEM, with n representing the
number of slices. Simple two group comparisons were
performed using Student's t-test. Multiple group means
were compared by analyses of variance (ANOVA), fol-
lowed by a Tukey post hoc test. The minimal significance
level for tests was set at p < 0.05. Graphs are expressed in
percentage of control, where the control for each slice rep-
resents the average of [DA] recorded in normal saline
before the entrance of the drug (T = 0 to T = 8). The
response after a drug application was then analysed by
comparing the maximal effect of the drug with the corre-
sponding time of the control graph.
List of abbreviations
NT: neurotensin; DA: dopamine; FCV: fast-scan cyclic vol-
tammetry; VTA: ventral tegmental area; NAcc: nucleus
accumbens; aCSF: artificial cerebrospinal fluid; TTX: tetro-
dotoxin; ANOVA: analysis of variance; NTR1: type 1 neu-
rotensin receptor.
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